|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suri V and Arora A: Management of
endometrial cancer: A review. Rev Recent Clin Trials. 10:309–316.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gunderson CC, Fader AN, Carson KA and
Bristow RE: Oncologic and reproductive outcomes with progestin
therapy in women with endometrial hyperplasia and grade 1
adenocarcinoma: A systematic review. Gynecol Oncol. 125:477–482.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hahn HS, Yoon SG, Hong JS, Hong SR, Park
SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, et al: Conservative
treatment with progestin and pregnancy outcomes in endometrial
cancer. Int J Gynecol Cancer. 19:1068–1073. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Horton JD, Goldstein JL and Brown MS:
SREBPs: Activators of the complete program of cholesterol and fatty
acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li JN, Mahmoud MA, Han WF, Ripple M and
Pizer ES: Sterol regulatory element-binding protein-1 participates
in the regulation of fatty acid synthase expression in colorectal
neoplasia. Exp Cell Res. 261:159–165. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swinnen JV: Increased lipogenesis in
steroid-responsive cancer cells: Mechanisms of regulation, role in
cancer cell biology and perspectives on clinical applications. Verh
K Acad Geneeskd Belg. 63:321–333. 2001.PubMed/NCBI
|
|
8
|
Yang Yu, Morin PJ, Han WF, Chen T, Bornman
DM, Gabrielson EW and Pizer ES: Regulation of fatty acid synthase
expression in breast cancer by sterol regulatory element binding
protein-1c. Exp Cell Res. 282:132–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yahagi N, Shimano H, Hasegawa K, Ohashi K,
Matsuzaka T, Najima Y, Sekiya M, Tomita S, Okazaki H, Tamura Y, et
al: Co-ordinate activation of lipogenic enzymes in hepatocellular
carcinoma. Eur J Cancer. 41:1316–1322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T,
Zhong Z, McCue PA, Sang N, Ji JY, et al: Repression of endometrial
tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle.
11:2348–2358. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eberhard Y, Gronda M, Hurren R, Datti A,
Maclean N, Ketela T, Moffat J, Wraba JL and Schimmer AD: Inhibition
of SREBP1 sensitizes cells to death ligands. Oncotarget. 2:186–196.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamisuki S, Mao Q, Abu-Elheiga L, Gu Z,
Kugimiya A, Kwon Y, Shinohara T, Kawazoe Y, Sato S, Asakura K, et
al: A small molecule that blocks fat synthesis by inhibiting the
activation of SREBP. Chem Biol. 16:882–892. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shao W, Machamer CE and Espenshade PJ:
Fatostatin blocks ER exit of SCAP but inhibits cell growth in a
SCAP-independent manner. J Lipid Res. 57:1564–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Chen YT, Hu P and Huang WC:
Fatostatin displays high anti-tumor activity in prostate cancer by
blocking SREBP-regulated metabolic pathways and androgen receptor
signaling. Mol Cancer Ther. 13:855–866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Wu JB, Chung LW and Huang WC:
Anti-cancer efficacy of SREBP inhibitor, alone or in combination
with docetaxel, in prostate cancer harboring p53 mutations.
Oncotarget. 6:41018–41032. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siqingaowa, Sekar S, Gopalakrishnan V and
Taghibiglou C: Sterol regulatory element-binding protein 1
inhibitors decrease pancreatic cancer cell viability and
proliferation. Biochem Biophys Res Commun. 488:136–140. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tennant DA, Durán RV and Gottlieb E:
Targeting metabolic transformation for cancer therapy. Nat Rev
Cancer. 10:267–277. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ward PS and Thompson CB: Metabolic
reprogramming: A cancer hallmark even warburg did not anticipate.
Cancer Cell. 21:297–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deberardinis RJ, Sayed N, Ditsworth D and
Thompson CB: Brick by brick: Metabolism and tumor cell growth. Curr
Opin Genet Dev. 18:54–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Byrne FL, Poon IK, Modesitt SC, Tomsig JL,
Chow JD, Healy ME, Baker WD, Atkins KA, Lancaster JM, Marchion DC,
et al: Metabolic vulnerabilities in endometrial cancer. Cancer Res.
74:5832–5845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Williams KJ, Argus JP, Zhu Y, Wilks MQ,
Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN,
et al: An essential requirement for the SCAP/SREBP signaling axis
to protect cancer cells from lipotoxicity. Cancer Res.
73:2850–2862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Radhakrishnan A, Goldstein JL, McDonald JG
and Brown MS: Switch-like control of SREBP-2 transport triggered by
small changes in ER cholesterol: A delicate balance. Cell Metab.
8:512–521. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goldstein JL, DeBose-Boyd RA and Brown MS:
Protein sensors for membrane sterols. Cell. 124:35–46. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gholkar AA, Cheung K, Williams KJ, Lo YC,
Hamideh SA, Nnebe C, Khuu C, Bensinger SJ and Torres JZ: Fatostatin
inhibits cancer cell proliferation by affecting mitotic microtubule
spindle assembly and cell division. J Biol Chem. 291:17001–17008.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Johannes VS, Koen B and Guido V: Increased
lipogenesis in cancer cells: New players, novel targets. Curr Opin
Clin Nutr Metab Care. 9:358–365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu C, Dongol S, Lv QT, Gao X and Jiang J:
Sterol regulatory element-binding protein-1/fatty acid synthase
involvement in proliferation inhibition and apoptosis promotion
induced by progesterone in endometrial cancer. Int J Gynecol
Cancer. 23:1629–1634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hatzivassiliou G, Zhao F, Bauer DE,
Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA and
Thompson CB: ATP citrate lyase inhibition can suppress tumor cell
growth. Cancer Cell. 8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Igal RA: Stearoyl-CoA desaturase-1: A
novel key player in the mechanisms of cell proliferation,
programmed cell death and transformation to cancer. Carcinogenesis.
31:1509–1515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo D, Bell EH and Chakravarti A: Lipid
metabolism emerges as a promising target for malignant glioma
therapy. CNS Oncol. 2:289–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Freeman MR, Cinar B, Kim J, Mukhopadhyay
NK, Di Vizio D, Adam RM and Solomon KR: Transit of hormonal and EGF
receptor-dependent signals through cholesterol-rich membranes.
Steroids. 72:210–217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lingwood D and Simons K: Lipid rafts as a
membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pandyra AA, Mullen PJ, Goard CA, Ericson
E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, et al:
Genome-wide RNAi analysis reveals that simultaneous inhibition of
specific mevalonate pathway genes potentiates tumor cell death.
Oncotarget. 6:26909–26921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wiemer AJ, Hohl RJ and Wiemer DF: The
intermediate enzymes of isoprenoid metabolism as anticancer
targets. Anticancer Agents Med Chem. 9:526–542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nevadunsky NS, Van Arsdale A, Strickler
HD, Spoozak LA, Moadel A, Kaur G, Girda E, Goldberg GL and Einstein
MH: Association between statin use and endometrial cancer survival.
Obstet Gynecol. 126:144–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vyas VK, Chintha C and Pandya MR: Biology
and medicinal chemistry approaches towards various apoptosis
inducers. Anticancer Agents Med Chem. 13:433–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Soldatenkov VA and Potaman VN: DNA-binding
properties of poly(ADP-ribose) polymerase: A target for anticancer
therapy. Curr Drug Targets. 5:357–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
